Letter from the Chair of the Organizing Committee

 

On behalf of the Chinese Biopharmaceutical Association (CBA), the biggest Chinese professional association in the biopharmaceutical industry in the US, we are proud to inform you that CBA and Guangdong provincial government will cohost CBA’s 14 the annual conference and Guangdong’s 1^st Pearl River International Forum at Guangzhou Baiyun International Convention Center on June 18-20, 2009.

 

Supported by Guangdong Provincial government, the Ministry of Science & Technology, the Overseas Chinese Affairs Office, the Ministry of Health, and the State Food and Drug Administration, the conference is designed to create a platform for communication and collaboration among biopharmaceutical companies, CROs, research institutions, government agencies, as well as individual research scientists, entrepreneurs, and venture capitalists. The theme of this joint conference is Biopharmaceutical Innovation and Commercialization, and sessions of this conference include the following:

     

·          Prospect of Stem Cell Therapy for Major Diseases

·          Preclinical and Clinical Outsourcing in China

·          Opportunities and Challenges for the Chinese Bio-pharmaceutical Industry

·          Technology Transfer, Investment and Partnership

·          Drug Innovation and Development

 - Monoclonal Antibody and RNAi Therapeutics

 - Diagnostics and Small Molecule Therapeutics

·          Intellectual Property, and Legal and Regulatory Issues

·          Regulatory Path of Traditional Chinese Medicine into the Global Market

·          Generic Drug Development and Interacting with FDA

 

In addition, CBA is organizing a pre-conference meeting on New Drug Discovery and Development and post-conference tours to the high-tech parks in Guangdong. The goal of the pre-conference meeting and the post-conference tours is to foster collaborations between high-end overseas talents and local companies and high-tech parks. These activities are free of charge to the main conference attendees.

 

We invite you to attend this joint conference, and we are confident you and your organization will benefit from this unique learning and networking opportunity. See you in Guangzhou!

 

Sincerely yours,

 

 

Yifan Zhai, M.D., Ph.D.                                               Huarong Yao, Director                                     
President-Elect , CBA                                       Guangdong Provincial Department of Science and Technology

Chair, Organizing Committee                           Co-Chair, Organizing Committee

The 14^th CBA Annual Conference & 1^st Pearl River International Biopharmaceutical Forum

 

 

 

 

 

Dear prospective sponsors, by sponsoring this conference, your company has a chance to

 

·       Showcase your company’ products to thousands of conference attendees,

·       Promote your company’s services to potential clients,

·       Identify prospective clients among conference attendees and organizations they represent,

·       Establish collaborations with other companies and individuals,

·       Gain access to CBA’s huge talent pools (more than 2000 members),

·       Learn current trend in the global biopharmaceutical industry, and

·       Learn the most recent SFDA and US FDA regulations

 

Depending on the level of your sponsorship, your company may receive additional benefits listed below:

 

·       A privilege of being listed as CBA’s Platinum Institutional Member in the 2009 annual conference program, proceedings, and on CBA’s web site,

·       Advertisement in the conference program and proceedings,

·       Exhibition opportunity at the conference site,

 

Contact us at contact@cba-usa.org, if you are interested in sponsoring the conference.

 

 

 

 

 

 

CBA strives to best serve its members. That’s the organizing committee of CBA’s 14^th annual conference prepared a special benefit package for CBA’s ACTIVE members.

 

Benefits for active CBA members include the following:

 

·        Free accommodation (double-room) at a hotel near the conference

·        Free meals during the conference

·        Optional tours to selected biopharmaceutical companies and high-tech parks in Guangdong, Suzhou, and Chengdu. 

 

For further information about the conference, please visit www.cba-usa.org or www.bio-pearlriver.com.

 

To take advantage of this benefit, please

 

v    Renew your CBA membership immediately if your membership has expired.

 

v    Join CBA at http://www.cba-usa.org/UserReg/register.php if you are not yet a CBA member.

 

 

 

 

 

 

CBA cherishes its partnership with member organizations of ALL-CABPA, including CABS, SABPA, and CABA. To honor ALL-CABPA and to appreciate all the supports these 3 organizations have been giving to CBA, the organizing committee of CBA’s 14^th annual conference has decided that members of each of these organizations who register to attend CBA’s annual conference in Guangzhou will have the privilege to enjoy above benefits as current CBA members do.  Register early at www.cba-usa.org to take advantage of the benefits.

 

 

 

 

 

Keynote Speakers

 

Dr. Luc Montagnier, Professor at the Institut Pasteur in Paris, 2008 Nobel Laureate in Medicine

Dr. Barry Sharpless, W. M. Keck Professor of Chemistry, The Scripps Research Institute (TSRI), 2001 Nobel Laureate in Chemistry

Dr. Robert C. Gallo, Professor and Director, University of Maryland, Baltimore; Member of the

National Academy of Sciences

Dr. Nanshan Zhong, President of Chinese Medical Association, Member of Chinese Academy of

Engineering

Dr. Ronald A. DePinho, M.D., Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, American Cancer Society Professor, Professor of Medicine and Genetics, Harvard Medical School

Mr. Sean Darragh, Executive Vice President, Biotechnology Industry Association (BIO)

Dr. Brian Leyland-Jones, Georgia Cancer Coalition Distinguished Scholar and Professor and Director, Winship Cancer Institute, Emory University

Dr. Jack Killen, Jr., Deputy Director, National Center for Complementary and Alternative Medicine (NCCAM) and Director, Office of International Health Research

 

Regular Speakers

 

Randall D. Mckinnon, Associate Professor at Robert Wood Johnson Medical School

Duanqing Pei, Professor and Director of Guangzhou Institute of Biomedicine and Health, CAS

Yufang Shi, Professor and Director of Institute of Health Sciences, SIBS, CAS

Yun-Bo Shi, Chief of Section on Molecular Morphogenesis, NICHD, NIH

Pu Paul Liu, Senior Investigator and Section Head, NHGRI, NIH

Devyn Smith, Principal, Frankel Group, LLC

Stephen Porter, CSO, Medicilon-MPI Preclinical Research, Shanghai

Chen Wen, Vice President, Tigermed Consulting Ltd

Shenming Wang, President, the First Affiliated Hospital, Sun Yat-sen University

Darren Ji, CEO, Pharmalegacy Laboratories

Jing-shan Hu, Director, Licensing and External Research, Merck & Co., USA

Yingfei Wei, CSO, 3S Bio

Haibin Wang, Hisun Pharma

Peng Wang, CSO, Simcere

Guoliang Yu, CEO, Epitomics, Inc

Xielong Luo, Beijing Medical Group

Jeffery Hung, SA Biosciences

Stella Xu, Executive Director, Roche Pharma Parterning

David Wang, Managing Director, WI Harper

Yi Shi, Managing Director, Eli Lilly Asia Venture

Goro Takeda, Managing Partner, FGC&Sofinnova

Xian-Ping Lu, CFO&CSO, Chipscreen Biosciences

Hao Lu, President and Partner, SAIF Partners

Larry Witte, Senior VP at ImClone System, a wholly-owned subsidiary of Eli Lilly and Company

Joe Zhou, CEO, Wilson-Bioengineering Company

Feng Li, Senior Engineering, Group Leader, Genentech

Luyuan Li, Professor, Nankai University, China

David Evans, VP of Discover Research, Sirnomics Inc.

Biliang Zhang, professor, Gaungzhou Institute of Biomedicine and Health, CAS

James Li, CEO, Cellex Inc.

Jie Wu, Senior Research Scientist and full professor, St. Joseph's Hospital & Medical Center

SuiXiong Cai, Senior Director of Chemistry, Epicept Corporation

Wei Zhou, Partner, Wilson Sonsini

Cindy Fuchs, Branch Chief, Technology Transfer Branch, NIAID, NIH

Brenda Fielding, President, Regulus Pharmaceutical Consulting.

Adda Gogoris, Darby&Darby LLP

Nikolas Burlew, Vice President, Quality Systems, Sequoia Life Sciences

Tom Du, Chief Technology Officer, American Oriental Bioengineering, Inc.

Chun-Tao Che, Professor and Director, Scholl of Chinese Medicine, Chinese University of Hong Kong.

Chuanjian Lu, Professor, Vice President, Gaungdong Provincial Hospital of Chinese Medicine

Zaijie Wang, Associate Professor, Department of Biopharmaceutical Sciences, University of Illinois, Chicago

Jin-Rong Zhou, Ph.D., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School

John Hu, Ph.D., Vice President and General Manager, USP-China

 

 

 

 

 

·       Biotechnology Industry Organization (BIO)

·       Simcere Pharmaceutical Group

·       Tigermed Consulting Co. Ltd

·       Medicilon - MPI Preclinical Research, Shanghai

·       Fosun Pharma

·       Wuxi  App Tec Co. Ltd

·       Sequoia Life Sciences

·       Merck & Co., Inc

·       Hoffmann-La Roche Ltd.

·       Johnson and Johnson Services, Inc.

·       Wilson Sonsini Goodrich & Rosati Professional Corporation

·       Stealth Peptides, Inc.

·       Epitomics Inc.

·       Sirnaomics, Inc.

·       PharmaLegacy Laboratories Co., Ltd.

·       Fountain Medical Development Ltd

·       Life Technologies, Inc.

·       SA Biosciences, Inc.

·       Zenni Optical

·       Pinsent Masons LLP

·       ImClone Systems, a wholly-owned subsidiary of Eli Lilly and company

·       Maryland Department of Business and Economic Development

·       National Foundation for Cancer Research

·       Wuxi AppTec Co. Ltd